CompanyGraph
What stands out
- Earnings significantly exceed cash generation
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 5 industries, depends on 1
- ScaleMarket cap is $4.82B, above the global median of $1.15B
- PositionProfit margin is 197.7%, higher than 95% of its Medical Instruments & Supplies peers (median 7.4%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.18%Above 5Y avg (1.98%)
Annual Rate
CNY 1.65Paid unknown
Payout Ratio
3.8%Sustainable
Payback Period
42.8 yr
Last Ex-Dividend
Jun 3, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
- Valued far above the size of its business
Financials view
Market Capitalization
32.45BCNY4.82B · vs all stocks (USD)
Trailing P/E
13.99xvs Medical Instruments & Supplies peers
Revenue (TTM)
1.16BCNY172.29M · vs all stocks (USD)
Profit Margin
197.75%vs Medical Instruments & Supplies peers
Beta
-0.6130xvs all stocks
52-Week Change
67.45%vs all stocks
Forward Annual Dividend Yield
2.18%vs all stocks
Market Capitalization
32.45BCNY4.82B · vs all stocks (USD)
Enterprise Value
25.37BCNY3.77B · vs all stocks (USD)
Trailing P/E
13.99xvs Medical Instruments & Supplies peers
Price to Sales (TTM)
29.84xvs Medical Instruments & Supplies peers
Price to Book (MRQ)
1.44xvs Medical Instruments & Supplies peers
Enterprise to Revenue
21.87xvs Medical Instruments & Supplies peers
Enterprise to EBITDA
-75.87xvs Medical Instruments & Supplies peers
Gross Margin
69.00%vs Medical Instruments & Supplies peers
Profit Margin
197.75%vs Medical Instruments & Supplies peers
Operating Margin
0.23%vs Medical Instruments & Supplies peers
Return on Assets (TTM)
-0.78%vs Medical Instruments & Supplies peers
Return on Equity (TTM)
10.55%vs Medical Instruments & Supplies peers
Revenue (TTM)
1.16BCNY172.29M · vs all stocks (USD)
Revenue per Share (TTM)
2.71CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-40.50%vs Medical Instruments & Supplies peers
Gross Profit (TTM)
693.01MCNY102.93M · vs all stocks (USD)
EBITDA (TTM)
543.11MCNY80.66M · vs all stocks (USD)
Net Income (TTM)
2.29BCNY340.70M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
10.20%vs Medical Instruments & Supplies peers
Operating Cash Flow (TTM)
-266.59MCNY-39.59M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-348.49MCNY-51.76M · vs all stocks (USD)
Forward Annual Dividend Rate
1.65CNYUpdated Aug 20, 2026Forward Annual Dividend Yield
2.18%vs all stocks
Trailing Annual Dividend Rate
1.65CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
2.18%vs all stocks
5-Year Average Dividend Yield
1.98%vs all stocks
Payout Ratio
3.77%vs Medical Instruments & Supplies peers
Minority Interest (Equity)
202.75MCNYFY2025 · Dec 31, 2025Revenue
1.37BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
493.97MCNYFY2025 · Dec 31, 2025Gross Profit
871.62MCNYFY2025 · Dec 31, 2025Operating Income
-296.54MCNY-44.04M · vs all stocks (USD)
Pre-tax Income
2.53BCNYFY2025 · Dec 31, 2025Income Tax Expense
257.75MCNYFY2025 · Dec 31, 2025Net Income
2.27BCNYFY2025 · Dec 31, 2025EBIT
2.64BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
633.46MCNYFY2025 · Dec 31, 2025Research & Development
323.57MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
524.18MCNYFY2025 · Dec 31, 2025Other Operating Expenses
2.65MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
139.09MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
113.52MCNYFY2025 · Dec 31, 2025EPS (Basic)
5.23CNYFY2025 · Dec 31, 2025EPS (Diluted)
5.21CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
433.48MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
433.48MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
2.27BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-2.76MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
2.44BCNYFY2025 · Dec 31, 2025Free Cash Flow
2.18BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.39BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
2.27BCNYFY2025 · Dec 31, 2025Other Non-cash Items
120.26MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-28.20MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
83.14MCNYFY2025 · Dec 31, 2025Capital Expenditures
-261.95MCNYFY2025 · Dec 31, 2025Net Acquisitions
-962.89KCNYFY2025 · Dec 31, 2025Purchase of Investments
-11.75BCNYFY2025 · Dec 31, 2025Sale of Investments
11.30BCNYFY2025 · Dec 31, 2025Other Investing Activity
-15.45MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-728.45MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
9.12BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-6.80BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-186.91MCNYFY2025 · Dec 31, 2025Other Financing Charges
-1.61BCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
523.69MCNYFY2025 · Dec 31, 2025Shares Outstanding
465.11MSharesUpdated Aug 20, 2026Float Shares
283.64MSharesUpdated Aug 20, 2026% Held by Insiders
30.89%vs all stocks
% Held by Institutions
7.93%vs all stocks
Total Cash (MRQ)
13.00BCNY1.93B · vs all stocks (USD)
Total Cash per Share (MRQ)
31.05CNYUpdated Aug 20, 2026Total Debt (MRQ)
6.51BCNY967.51M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2985xvs Medical Instruments & Supplies peers
Current Ratio (MRQ)
2.93xvs Medical Instruments & Supplies peers
Book Value per Share (MRQ)
51.66CNYUpdated Aug 20, 2026Total Assets
29.31BCNY4.35B · vs all stocks (USD)
Total Current Assets
11.94BCNYFY2025 · Dec 31, 2025Total Liabilities
7.28BCNYFY2025 · Dec 31, 2025Total Non-current Assets
17.38BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
2.77BCNYFY2025 · Dec 31, 2025Total Current Liabilities
4.51BCNYFY2025 · Dec 31, 2025Cash
2.34BCNYFY2025 · Dec 31, 2025Cash Equivalents
981.75MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.33BCNYFY2025 · Dec 31, 2025Other Short-term Investments
7.36BCNYFY2025 · Dec 31, 2025Accounts Receivable
47.91MCNYFY2025 · Dec 31, 2025Inventory
204.23MCNYFY2025 · Dec 31, 2025Accounts Payable
62.64MCNYFY2025 · Dec 31, 2025Short-term Debt
4.20BCNYFY2025 · Dec 31, 2025Other Current Liabilities
388.53KCNYFY2025 · Dec 31, 2025Long-term Debt
1.48BCNYFY2025 · Dec 31, 2025Common Stock (Book)
464.94MCNYFY2025 · Dec 31, 2025Retained Earnings
20.29BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
22.03BCNY3.27B · vs all stocks (USD)
Treasury Stock
1.66BCNYFY2025 · Dec 31, 202552-Week Low
37.69CNYUpdated Aug 20, 202652-Week High
94.94CNYUpdated Aug 20, 202652-Week Change
67.45%vs all stocks
Beta
-0.6130xvs all stocks
50-Day MA
68.36CNYUpdated Aug 20, 2026200-Day MA
58.87CNYUpdated Aug 20, 2026Avg 10-Day Volume
33.80MSharesUpdated Aug 20, 2026Avg 30-Day Volume
38.53MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
5.31CNYUpdated Aug 20, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
High ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration
Return on equity reads high, with a large gap between pretax and operating income.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 197.7%, higher than 95% of its Medical Instruments & Supplies peers (median 7.4%)Significant
Profit margin: 1.98Industry median: 0.07Industry P95: 0.36Peers compared: 35.00
P/E ratio is 13.99×, lower than 95% of its Medical Instruments & Supplies peers (median 41.06×)Notable
P/E ratio: 13.99Industry median: 41.06Industry P5: 15.01Peers compared: 35.00
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 340,704,784.947Operating Cash Flow (USD, TTM): -39,594,481.472
Valued far above the size of its businessSignificant
Price-to-Sales: 29.84Revenue Growth YoY: -0.41
Financial Health
Altman Z-Score 4.29: safe zoneNotable
Altman Z-Score: 4.29
High structural barrier to entryNotable
Barrier to Entry: 1.97
Supply Chain
Upstream position: supplies 5 industries, depends on 1Notable
Outgoing: 5.00Incoming: 1.00
Scale
Market cap is $4.82B, above the global median of $1.15BNotable
Market cap (USD): 4,820,092,994.23Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Guangdong Shenling Environmental Systems Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRule
Glarun Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Guizhou Space Appliance Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Castech Inc.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Sunwoda Electronic Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Cathay Biotech Inc.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Intco Medical Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Western Superconducting Technologies Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
RadNet Inc.
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Sunresin New Materials Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Keli Sensing Technology Nanjing Inc.
3 interpretationsHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin Elevated
Dalian Dalicap Technology Co., Ltd.
3 interpretationsHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin Elevated
Paramount Resources Ltd.
3 interpretationsHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedHigh ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration